Avagliano Mark 4
4 · G1 Therapeutics, Inc. · Filed Jan 5, 2023
Insider Transaction Report
Form 4
Avagliano Mark
Chief Business Officer
Transactions
- Award
Stock Options (Right to buy)
2023-01-03+41,100→ 41,100 totalExercise: $5.73Exp: 2033-01-03→ Common Stock (41,100 underlying) - Award
Common Stock
2023-01-03+20,600→ 42,155 total
Footnotes (4)
- [F1]Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]Each RSU represents a contingent right to receive one share of Issuer common stock.
- [F3]Represents (i) 7,055 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 20,600 RSUs from award granted on January 3, 2023.
- [F4]The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.